Bain Capital Life Sciences Healthcare News

This is selected healthcare news for Bain Capital Life Sciences, which is filed under Capital Firms. There are 135 news items for this page. A press release filter page is also available for Bain Capital Life Sciences.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/23/2022 Stock Market | Finance
... on November 22, 2022 -- -- Closed concurrent, oversubscribed and upsized approximately $235 million private investment in public equity (‚AuPIPE‚Au), led by Frazier Healthcare Partners and Bain Capital Life Sciences -- -- Gross proceeds from the transactions totaled approximately $328 million , combining approximately $93 million from the former FLAC trust account (reflecting a ...
azcentral.com
11/18/2022 The Week's 10 Biggest Funding Rounds: Health And Biotech Land Big Week As DispatchHealth Leads
... million, per Crunchbase. 6. Jnana Therapeutics , $107M, biotechnology: Boston-based Jnana Therapeutics, a clinical-stage biotechnology company, raised a $107 million Series C led by Bain Capital Life Sciences . Founded in 2017, the company has raised more than $200 million, according to Crunchbase. 7. Bonum Therapeutics , $93M, biotech: Seattle-based ...
crunchbase.com
11/17/2022 Jnana Therapeutics Raises Funding, Closes Deal with Roche
Jnana Therapeutics Raises Funding, Closes Deal with Roche Boston biotech Jnana Therapeutics has raised $107 million in a Series C financing led by Bain Capital Life Sciences. The proceeds from the funding will be used to progress the company's lead program in phenylketonuria (PKU), a rare genetic metabolic disease ...
ispeboston.org
11/15/2022 Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform
... platform to discover medicines for challenging-to-drug targets, today announced the close of its $107 million Series C financing. The financing was led by Bain Capital Life Sciences with participation from existing investors including RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures and Pfizer Ventures. "We are thrilled ...
salesandmarketingnetwork.com
11/15/2022 Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform
Series C financing led by Bain Capital Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana's Board of Directors Jnana initiates Phase 1 clinical trial of JNT-517, a potential first-in-class oral treatment for PKU; JNT-517 receives US ...
PR Newswire
11/15/2022 Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform
Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform Series C financing led by Bain Capital Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana's Board of Directors Jnana initiates Phase ...
Yahoo News
11/9/2022 Stock Market | Markets
... oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to ...
livermore.com
11/9/2022 Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer
... oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to ...
Yahoo News
11/9/2022 Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer | Business | The Daily News
... oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to ...
galvnews.com
11/6/2022 Biotech Funding Roundup: HI-Bio's Haul, Concerto's Cash, Lusaris's Launch & More - MedCity News
... of the drugs currently available to treat the muscle and vocal tics caused by Tourette. Emalex's Series D round of funding was led by Bain Capital Life Sciences. Photo: RomoloTavani , Getty Images ...
MedCity News
11/3/2022 Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug - MedCity News
... target and the biotech has raised $250 million for a Phase 3 clinical trial. The Series D round of financing announced Thursday was led by Bain Capital Life Sciences. The exact cause of Tourette syndrome is unknown but excess activity of a brain chemical called dopamine is thought to play ...
MedCity News
10/25/2022 JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical Officer
... indicated for the treatment of AR. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners (formerly Edmond de Rothschild Investment Partners), Valiance Life Sciences, Gimv, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI ...
cardiacvascularnews.com
10/24/2022 JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical
... indicated for the treatment of AR. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners (formerly Edmond de Rothschild Investment Partners), Valiance Life Sciences, Gimv, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI ...
Globe Newswire
10/24/2022 JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical Officer
... indicated for the treatment of AR. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners (formerly Edmond de Rothschild Investment Partners), Valiance Life Sciences, Gimv, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI ...
Yahoo News
10/24/2022 JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical Officer
... indicated for the treatment of AR. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners (formerly Edmond de Rothschild Investment Partners), Valiance Life Sciences, Gimv, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI ...
healthtechnologynet.com
10/20/2022 Ten Tips For Baby Products Home Delivery
... Kellaher, Colin (September 12, 2019). "SpringWorks Raises IPO to 9 Million Shares at $16-$18 Each". Gompers, Paul; Ivashina, Victoria; Ruback, Richard (2019). Private Equity. Bain Capital Life Sciences invests in corporations that concentrate on medical innovation and serve patients wi... https://www.babystufflab.com/best-kid-galaxy-boats ...
bookmark-dofollow.com
10/7/2022 Rivus Pharma raises $132M in series B
... development of HU6, a drug candidate that treats cardiometabolic disease by addressing obesity. The funding round was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors, according to the Sept. 22 Rivus news release. "We have an exceptional group of investors ...
Becker's Hospital Review
10/6/2022 Eight Tips For Baby Products Home Delivery
... Kellaher, Colin (September 12, 2019). "SpringWorks Raises IPO to 9 Million Shares at $16-$18 Each". Gompers, Paul; Ivashina, Victoria; Ruback, Richard (2019). Private Equity. Bain Capital Life Sciences invests in firms that concentrate on medical innovation and serve patients with unme... http://idea.informer.com/users/ulriksen10fr/?what=personal ...
getsocialpr.com
10/3/2022 North America's medical devices industry saw a drop of 22.52% in deal activity during August 2022
... the overall value of $1.4bn deals Teleflex's $300m acquisition deal with Standard Bariatrics 2) The $250m acquisition of Biorez by ConMed 3) Andera Partners, Bain Capital Life Sciences, Cormorant Asset Management, Gimv, Innovatus Capital Partners, Peijia Medical, Pictet Alternative Advisors, Qatar Investment Authority, RMM Consulting Group, Valiance Advisors and ...
medicaldevice-network.com
9/30/2022 Solid Bio gets a new CEO, $75M cash and drops lead as big investors rig a merger deal – Endpoints News
... combined operation, as Solid founder Ilan Ganot steps aside. The merger news this morning features some high-profile investors. Perceptive Advisors, RA Capital Management and Bain Capital Life Sciences are leading a $75 million raise to add to the pool of cash Solid will have after the tie-up. That ...
endpts.com
9/23/2022 Rivus raises $132m to advance clinical development of obesity treatment
Rivus Pharmaceuticals has raised $132m in a Series B funding round to clinically advance its lead candidate, HU6, for the treatment of obesity and cardio-metabolic disorders. RA Capital Management led the financing round, which also saw participation from Bain Capital Life Sciences and BB Biotech. Existing investors of the ...
pharmaceutical-technology.com
9/23/2022 Venture Capital: Rivus Pharma Lands $132M For Obesity and Cardio-Metabolic Drug
... as well as obesity, the primary driver of the disease. (CISION PR Newswire) The funding round was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. Cardio metabolic diseases affect nearly half of American adults and ...
dailyalts.com
9/23/2022 Rivus Pharmaceuticals Closes $132M Series B Financing
Rivus Pharmaceuticals Inc. , a Charlottesville, VA-based clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, completed a $132m Series B financing. The round was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. In ...
finsmes.com
9/22/2022 Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders
Financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and Series A investors Longitude Capital, Medicxi and RxCapital CHARLOTTESVILLE, Va. , Sept. 22, 2022 /PRNewswire/ -- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of ...
PR Newswire
9/22/2022 Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders
Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders Financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and Series A investors Longitude Capital, Medicxi and RxCapital CHARLOTTESVILLE, Va., Sept. 22, 2022 ...
cardiacvascularnews.com